| Autor: |
Wolf, M. Allison, O'Hara, Joanne M., Bitzer, Graham J., Narayanan, Elisabeth, Boehm, Dylan T., Bevere, Justin R., DeJong, Megan A., Hall, Jesse M., Wong, Ting Y., Falcone, Samantha, Deal, Cailin E., Richards, Angelene, Green, Shannon, Nguyen, Brenda, King, Emily, Ogega, Clinton, Russo, Lisa, Sen-Kilic, Emel, Plante, Obadiah, Himansu, Sunny |
| Předmět: |
|
| Zdroj: |
NPJ Vaccines; 6/10/2024, Vol. 9 Issue 1, p1-14, 14p |
| Abstrakt: |
Acellular multivalent vaccines for pertussis (DTaP and Tdap) prevent symptomatic disease and infant mortality, but immunity to Bordetella pertussis infection wanes significantly over time resulting in cyclic epidemics of pertussis. The messenger RNA (mRNA) vaccine platform provides an opportunity to address complex bacterial infections with an adaptable approach providing Th1-biased responses. In this study, immunogenicity and challenge models were used to evaluate the mRNA platform with multivalent vaccine formulations targeting both B. pertussis antigens and diphtheria and tetanus toxoids. Immunization with mRNA formulations were immunogenetic, induced antigen specific antibodies, as well as Th1 T cell responses. Upon challenge with either historical or contemporary B. pertussis strains, 6 and 10 valent mRNA DTP vaccine provided protection equal to that of 1/20th human doses of either DTaP or whole cell pertussis vaccines. mRNA DTP immunized mice were also protected from pertussis toxin challenge as measured by prevention of lymphocytosis and leukocytosis. Collectively these pre-clinical mouse studies illustrate the potential of the mRNA platform for multivalent bacterial pathogen vaccines. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink